Forte Biosciences, Inc. on May 12, 2022, the Board of Directors of the company, upon recommendation of the Nominating and Governance Committee of the Board, appointed Stephen K. Doberstein, Ph.D. to the Board, effective May 12, 2022. Doberstein will serve as a Class I director, with a term expiring at the annual meeting of stockholders to be held in 2024. Doberstein is a principal of Kahiliholo Consulting, LLC, since February 2020.

Dr. Doberstein previously served as Senior Vice President and Chief Scientific Fellow of Nektar Therapeutics, Inc., from October 2019 to March 2020.